ZVRA
Zevra Therapeutics Inc.
11.10$
+3.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.6% | 50.4% | 41.6% | 42.2% | 51.9% | 48.3% | 47.2% | 88.3% | 83.3% | 78.3% | 82.6% | 83.0% | |
| 31.1% | 25.0% | 28.3% | 27.2% | 28.2% | 19.0% | 21.6% | 18.6% | 20.2% | 21.9% | 34.3% | 48.0% | |
| 60.0% | – | 34.8% | 34.1% | 46.7% | 39.0% | 36.3% | 79.1% | 73.9% | 67.1% | 34.3% | 73.2% | |
| 7.1% | 9.4% | 5.5% | 6.2% | 4.1% | 5.9% | 7.3% | 7.1% | 6.2% | 8.2% | 7.9% | 7.4% | |
| – | 0.0% | 8.2% | 7.1% | 4.6% | 1.1% | 1.5% | 0.4% | 0.5% | 0.6% | 0.8% | 0.8% | |
| – | 2.7% | 3.1% | 3.3% | 2.5% | 2.6% | 2.7% | 1.8% | 1.7% | 1.7% | 1.7% | 1.6% | |
| – | 40.2% | 44.7% | 45.8% | 36.9% | 38.7% | 39.0% | 2.8% | 2.5% | 2.3% | 2.2% | 1.9% | |
| 51.5% | 64.1% | 67.7% | 77.5% | 63.6% | 77.7% | 76.2% | 54.3% | 50.7% | 45.7% | 26.1% | 28.1% | |
| 15.6% | 42.8% | 19.8% | 21.1% | 18.0% | 19.1% | 15.6% | 11.3% | 9.7% | 13.8% | 16.9% | 16.1% | |
| 0.3% | – | 0.4% | 0.4% | 0.3% | 0.2% | 0.3% | 0.2% | 0.2% | 0.1% | 0.1% | 0.2% | |
| 8.5% | 8.1% | 15.1% | 14.2% | 12.8% | 7.3% | 10.3% | 6.2% | 4.1% | 0.9% | 4.2% | 4.6% | |
| 31.6% | 2.9% | 28.4% | 40.4% | 30.8% | 33.4% | 34.8% | 23.7% | 22.7% | 21.7% | – | – | |
| 48.5% | 35.9% | 32.3% | 22.5% | 36.4% | 22.3% | 23.8% | 45.7% | 49.3% | 54.3% | 73.9% | 71.9% | |
| -244.3% | -232.0% | -275.2% | -302.1% | -245.1% | -283.7% | -294.4% | -169.2% | -160.8% | -148.2% | -137.9% | -124.0% | |
| 25.0% | 24.1% | 27.6% | 29.0% | 25.0% | 30.1% | 31.3% | 22.0% | 20.7% | 20.1% | 21.6% | 20.3% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.